[HTML][HTML] Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older
…, F de Looze, HJ Downey, W Ghesquiere… - … England Journal of …, 2016 - Mass Medical Soc
Background A trial involving adults 50 years of age or older (ZOE-50) showed that the herpes
zoster subunit vaccine (HZ/su) containing recombinant varicella–zoster virus glycoprotein …
zoster subunit vaccine (HZ/su) containing recombinant varicella–zoster virus glycoprotein …
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus …
E Lawitz, E Gane, B Pearlman, E Tam, W Ghesquiere… - The Lancet, 2015 - thelancet.com
Background There is a high medical need for an interferon-free, all-oral, short-duration
therapy for hepatitis C virus (HCV) that is highly effective across diverse patient populations, …
therapy for hepatitis C virus (HCV) that is highly effective across diverse patient populations, …
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis
…, J Vierling, B Freilich, J Cooper, W Ghesquiere… - Jama, 2015 - jamanetwork.com
Importance Effective and well-tolerated, interferon-free regimens are needed for treatment
of patients with chronic hepatitis C virus (HCV) infection and cirrhosis. Objective All-oral …
of patients with chronic hepatitis C virus (HCV) infection and cirrhosis. Objective All-oral …
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
C Hézode, GM Hirschfield, W Ghesquiere, W Sievert… - Gut, 2015 - gut.bmj.com
Objective To evaluate the safety and efficacy of daclatasvir, an HCV NS5A inhibitor with
pangenotypic activity, administered with peginterferon-alfa-2a/ribavirin. In this Phase 2b double-…
pangenotypic activity, administered with peginterferon-alfa-2a/ribavirin. In this Phase 2b double-…
[HTML][HTML] Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials
…, FA Caruntu, M Curescu, R Skoien, W Ghesquiere… - Journal of …, 2016 - Elsevier
Background & Aims Telaprevir plus pegylated interferon/ribavirin (TPV + PegIFN/RBV) remains
a therapeutic option for chronic hepatitis C virus (HCV) genotype (GT) 1 infection in many …
a therapeutic option for chronic hepatitis C virus (HCV) genotype (GT) 1 infection in many …
[HTML][HTML] Travel-acquired infections and illnesses in Canadians: surveillance report from CanTravNet surveillance data, 2009–2011
…, BJ Ward, AE McCarthy, PW Doyle, W Ghesquiere… - Open …, 2014 - ncbi.nlm.nih.gov
Background: Important knowledge gaps exist in our understanding of migration medicine
practice and the impact of pathogens imported by Canadian travellers. We present here a …
practice and the impact of pathogens imported by Canadian travellers. We present here a …
The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase 3 clinical …
…, M Esen, M Ferguson, W Ghesquiere… - Clinical Infectious …, 2022 - academic.oup.com
Background This ongoing follow-up study evaluated the persistence of efficacy and immune
responses for 6 additional years in adults vaccinated with the glycoprotein E (gE)-based …
responses for 6 additional years in adults vaccinated with the glycoprotein E (gE)-based …
Longitudinal Clinical Findings and Outcome Among Patients With Cryptococcus gattii Infection in British Columbia
Background. Cryptococcus gattii (Cg) infection emerged in British Columbia in 1999. A
longitudinal, clinical description of patients has not been reported. Methods. Medical records …
longitudinal, clinical description of patients has not been reported. Methods. Medical records …
[HTML][HTML] Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials
…, M Esen, E Espie, P Gervais, W Ghesquiere… - Vaccine, 2019 - Elsevier
Background The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials
showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in …
showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in …
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection
…, S Zaltron, SI Strasser, N Weis, W Ghesquiere… - Gastroenterology, 2015 - Elsevier
Background & Aims Twenty-four weeks of treatment with peginterferon and ribavirin for
chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic …
chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic …